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Abstract  
Purpose: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor 
symptoms in postmenopausal women. We have done an exploratory, double-blind, randomized, placebo-
controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on breast cancer in 
postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma 
carcinoma tissue). 
Experimental Design: Postmenopausal women with initially stage I/II, estrogen receptor -positive (ER + ) 
primary breast cancer, were randomly assigned to 14 days of placebo or 2.5 mg/d tibolone. Core biopsies of the 
primary tumor were obtained before and after treatment. Ki-67 and apoptosis index were analyzed in baseline 
and corresponding posttreatment specimen.  
Results: Of 102 enrolled patients, 95 had evaluable data. Baseline characteristics were comparable between both 
treatment groups. Breast cancer cases are mainly invasive (99%), stage I or II (42% and 50% respectively), and 
ER+ (99%). Median intratumoral Ki-67 expression at baseline was 13.0% in the tibolone group and 17.8% in the 
placebo group, and decreased to 12.0% after 14 days of tibolone while increasing to 19.0% in the placebo group. 
This change from baseline was not significantly different between tibolone and placebo (Wilcoxon test; P = 
0.17). A significant difference was observed between the treatment groups when the median change from 
baseline apoptosis index was compared between the treatment groups (tibolone, 0.0%; placebo, +0.3%; 
Wilcoxon test; P = 0.031). The incidence of adverse effects was comparable.  




Vasomotor symptoms are a major side effect of adjuvant breast cancer treatment and it has been estimated that 
up to 96% of women who undergo chemotherapy or endocrine therapy suffer from hot flashes or night sweats 
(1). Although these symptoms are thought to result from systemic estrogen and progestin deprivation and can 
effectively be treated by hormone replacement therapy in patients who are not taking tamoxifen, such a 
therapeutic strategy is contraindicated, mainly because of a fear of the proliferative and tumor-promoting effects 
attributed to sex steroids (2). Unfortunately, the efficacy and safety of phytoestrogens as alternatives in the 
treatment of vasomotor symptoms is unproven and nonhormonal therapies with serotonin reuptake inhibitors and 
gaba-pentin are, at best, approximately half as effective as estrogen (3, 4). In addition, nonhormonal therapies 
have no effect on other postmenopausal symptoms such as bone loss or urogenital atrophy (5). 
Tibolone (Livial) is a selective tissue estrogenic activity regulator, approved for the treatment of climacteric 
symptoms in postmenopausal women. Following oral administration, it is converted into three primary 
metabolites, of which the 3α-hydroxymetabolite and the 3β-hydroxymetabolite only bind to the estrogen receptor 
α, whereas the parent compound tibolone and its ∆4-isomer bind to the progesterone and androgen receptors.  
The metabolism is tissue specific and results in a highly favorable profile of effects: Although tibolone exerts 
estrogenic effects on bone, brain, and the urogenital system through its hydroxymetabolites, it does not seem to 
stimulate endometrium or to increase breast tissue proliferation (6). It has been proposed that the lack of an 
estrogenic effect on breast tissue may result from the inhibition of sulfatase and the stimulation of 
sulfotransferase in this tissue (7, 8). Indeed, clinical studies have shown that compared with women who use 
continuous combined hormone treatment, tibolone users experience considerably less breast tenderness and do 
Published in: Clinical Cancer (2007), vol. 13, iss. 14, pp. 4185-4190 
Status: Postprint (Author’s version) 
 
not develop an increase in mammographic density (9). Breast safety studies in the                                                     
7,12-dimethylbenz(α)anthracene model have shown that tibolone is highly effective in reducing tumor growth in 
mice (10). In addition, tibolone inhibits the sulfatase enzyme and promotes apoptosis in normal as well as breast 
cancer cells, thus suggesting a local antiestrogenic effect (11). The observation that tibolone is also able to 
decrease the proliferation rate of normal and malignant breast epithelial cells in vitro warrants particular 
attention (12, 13, 14). Dowsett et al. (15) have recently shown that the nuclear antigen Ki-67, which is expressed 
in proliferating cells, is an appropriate end point in neoadjuvant models of response to long-term endocrine 
therapies. 
We have therefore studied tissue-specific effects of 14 days of 2.5 mg tibolone on breast cancer in 
postmenopausal women, in particular on the proliferation marker Ki-67 and on apoptosis, to support the 
hypothesis that tibolone has no adverse effects on malignant breast tissue. 
PATIENTS AND METHODS 
Study design. The STEM (Study of Tibolone Effects on Mamma carcinoma tissue) study is a randomized, 
placebo-controlled, double-blind, multicenter, exploratory trial, in which postmenopausal women with initially 
stage I or II, estrogen receptor-positive (ER+) primary breast cancer were randomized 1:1 to receive a 
preoperative daily oral dose of 2.5 mg tibolone, or placebo for 14 days until surgery. Eligible patients had 
previously untreated, core-biopsy proven, invasive breast cancer without evidence of metastatic spread and any 
endocrine or enzyme modulator therapy was stopped at least 3 months before randomization. 
Objectives. The aim of the trial was to confirm the safety of tibolone on breast tissue in women with early breast 
cancer as measured by the breast safety surrogate variables Ki-67 and apoptosis index. The primary trial 
objective was to compare changes in the expression of the proliferation marker Ki-67 label index in malignant 
breast tissue after treatment with tibolone or placebo for 14 days. Secondary objectives were the evaluation of 
treatment effects on tumor apoptosis index, on apoptosis-related proteins Bcl-2 and Bax, hormone receptors, 
hormone-sensitive proteins, tumor vascularization, and angiogenesis. Moreover, endogenous estrogen levels and 
tibolone and tibolone metabolites in serum and breast tissue were measured. In addition, monitoring of (serious) 
adverse events, clinically significant abnormal laboratory values and summary statistics for vital signs was done 
to evaluate the overall safety of tibolone in women with early breast cancer. Although we here report the effect 
of tibolone, compared with placebo, on tumor proliferation and apoptosis and on overall safety in women with 
early breast cancer, other secondary end points will be presented elsewhere. The study was done in accordance 
with the ethical principles of the Declaration of Helsinki and was approved by the local institutional review 
board at all study sites. Only women who had given written voluntary informed consent were included into the 
trial. Block randomization was done per center to ensure that treatments were equally distributed in each of the 
participating centers. In total, 102 women were randomized in 14 sites in five countries between March 2003 and 
April 2005. Patient and tumor characteristics of women randomized into the tibolone and the placebo arm are 
depicted in Table 1. 
Tumor assessments. Tumor samples were obtained by core biopsies at screening and after 14 days of treatment 
with study medication from the excised tumor at surgery. A minimum of three core biopsy samples was required 
per biopsy site to ensure a representative evaluation of proliferation and apoptosis. For each patient, Ki-67 and 
apoptosis index were analyzed, by immunohistochemistry, in both baseline and the corresponding posttreatment 
excision samples. Measurement of cell proliferation was done by using the MIB1 mouse monoclonal antibody to 
Ki-67 and counting the number of positive cells in a random sample of 1,000 cells. Apoptotic cells were 
identified by immunostaining using the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-
labeling method. The apoptotic index was expressed as a percentage of the total number of cells displaying 
apoptotic bodies in a random sample of 1,000 cells. The relative Bcl-2 and Bax gene expression was determined 
by semiquantitative reverse transcription-PCR after extraction from snap-frozen tissue samples. Relative values 
were expressed as the ratio of specific transcripts/28S transcripts. All reverse transcription-PCR experiments 
were carried out at least thrice in duplicate on two different cDNA preparations. 
Statistical measurements. For all breast tissue safety variables, descriptive summary statistics, number (n), 
median, mean, and SE were calculated for the intent-to-treat group. Subjects within this intent-to-treat group 
have received trial treatment (placebo or tibolone) and also have had a post-baseline assessment on Ki-67. The 
safety of tibolone versus placebo on the breast was explored by comparing the postbaseline change from baseline 
measurements of Ki-67, apoptosis index, and the relative gene expression levels of Bcl-2 and Bax by Wilcoxon 
tests. All analyses were done using SAS Version 8.2 or higher under Windows NT. 
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Table 1. Baseline patient characteristics (intent-to-treat group) 
Variable Tibolone (n = 46) Placebo (n = 49) 
 Median Mean (SE) Median Mean (SE) 
Age (y) 66 64.8 (1.1) 65 65.1 (1.1) 
Weight (kg) 71 70.6 (1.3) 70 70.2 (1.3) 
Height (cm) 161 160.8 (1.2) 160 160.6 (1.2) 
BMI (kg/m2) 28 27.4 (0.5) 28 27.2 (0.5) 
Age at last menses (y) 50 48.4 (0.8) 49 48.1 (0.8) 
Time since menopause (y) 17.1 16.4 (1.4) 14.6 17.0 (1.4) 
Frequency distribution Tibolone (n = 46) Placebo (n = 49) 
ER at screening (%)   
      Positive 46 (100%) 49 (100%) 
Tumor stage, clinical (%)   
      I 18 (39%) 21 (43%) 
      II 24 (52%) 24 (49%) 
      III 2 (4%) 3 (6%) 
      IV 0 (0%) 1 (2%) 
      Unknown 2 (4%) 0 (0%) 
 
Table 2. Changes in intratumoral Ki-67 protein expression in response to 14 d of treatment (intent-to-treat 
group) 
 Baseline Surgery Change from baseline P* 
 Tibolone Placebo Tibolone Placebo Tibolone Placebo  
Ki-67 (%)       0.170 
     n 46 49 46 49 46 49  
     Median 13.0 17.8 12.0 19.0 -2.4 0.2  
     Mean (SE) 18.2 (2.2) 21.6 (2.8) 16.3 (2.3) 22.0 (2.4) -1.9 (2.1) 0.4 (1.2)  
NOTE: n = number of patients. Wilcoxon test on treatment differences for change from baseline. 
 
RESULTS 
Patients. The study cohort consisted of elderly (mean age ~ 65 years), postmenopausal women with a mean 
body mass index of slightly over 27 years, who suffered from breast cancer. There were no significant 
differences between the groups at baseline. At screening, tumor status in ~ 90% of patients was ER+ and also 
tumor staging was comparable between groups. Although at the time of randomization, all patients presented 
with stage I and II disease, the complete postoperative histologic evaluation of tumor size and lymph node 
involvement resulted in an upstaging in six patients. The main patient characteristics are presented in Table 1 for 
the intent-to-treat group. 
Intratumoral Ki-67 protein expression in pretherapeutic and posttherapeutic breast cancer biopsies. Table 
2 shows the intratumor levels of Ki-67 at baseline and after 14 days of trial treatment. The median baseline Ki-67 
levels were 13.0% in the tibolone arm and 17.8% in the placebo arm, whereas median posttreatment levels 
ranged from 12.0% in the tibolone arm to 19.0% in the placebo arm. The difference between the treatment 
groups in changes from baseline in intratumoral Ki-67 expression of -2.4% in the tibolone group and of +0.2% in 
the placebo group was nonsignificant (Wilcoxon test, P = 0.17). The individual changes from baseline in Ki-67 
are presented in Fig. 1. 
Intratumoral apoptosis index and Bcl-2 and Bax gene expression in response to tibolone. The intratumoral 
apoptosis index measured at baseline and after 14 days of treatment with 2.5 mg tibolone or placebo are shown 
in Table 3 for the intent-to-treat group. The median pretreatment apoptosis index in both the tibolone arm and the 
placebo arm was 1.4%, whereas the mean posttreatment apoptosis index was 1.6% in the tibolone arm, and 1.7% 
in the placebo arm. The resulting net changes in the median intratumoral apoptosis index were 0.0% in the 
tibolone group and 0.3% in the placebo group (Wilcoxon test on treatment differences P = 0.03). 
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Summary statistics of apoptosis-related proteins Bcl-2 and Bax mRNA expression at baseline and surgery 
showed similar results (Table 3). Median values of the antiapoptotic marker Bcl-2 and the proapoptotic marker 
Bax were not changed significantly by either tibolone or placebo (Wilcoxon test: Bax, P = 0.739; Bcl-2, P = 
0.642). 
Overall patient safety. Treatment with 2.5 mg tibolone for 14 days was safe and well tolerated. No significant 
differences between tibolone and placebo were observed with respect to the incidence and type of adverse events 
(Table 4). The most frequent adverse events during tibolone treatment were postprocedural pain (13.7%), 
asthenia (10%), and pyrexia (8%). Two serious adverse events occurred, an ischemic stroke in the tibolone group 
and a postoperative wound infection in the placebo group. Tibolone treatment was only discontinued once (2%), 
in response to one serious adverse event (ischemic stroke). As expected, treatment with 2.5 mg tibolone for 14 
days did not significantly alter blood pressure or heart rate (data not shown). 
DISCUSSION 
It is estimated that ~ 70% of women who suffer from breast cancer are postmenopausal. The remaining 30% will 
often become postmenopausal as a result of their cancer treatment. Climacteric symptoms are thus an 
increasingly relevant side effect of antineoplastic strategies, and associated symptoms such as hot flashes and 
night sweats can considerably affect quality of life (16). Although hormone treatment effectively ameliorates 
vasomotor symptoms, its use is contraindicated in women with a history of breast cancer. These 
recommendations are mostly based on the proliferative effect of estrogens on tumor cells in vitro, but also on 
epidemiologic evidence for an increase in breast cancer incidence that is especially strong in estrogen/progestin -
containing hormone replacement therapy formulations (17). At least three large trials have attempted to evaluate 
the safety of hormone replacement therapies in women with a history of breast cancer but none of them has been 
able to recruit sufficient patients, largely because of a fear of increased recurrence (18). A recently conducted 
metaanalysis of several smaller trials did not find an increase in breast cancer recurrence or in cancer-associated 
mortality with estrogen or estrogen progestin treatment, although one prospectively randomized trial was 
terminated early because of the finding that the treatment increased the risk of recurrence (19, 20). Thus far, no 
effective treatment for the alleviation of menopausal symptoms has been approved for women with breast 
cancer. 
Tibolone is a synthetic steroid that is distinct from currently available hormone treatment because of its mode of 
action and by its favorable clinical profile (21). In vitro, tibolone and its ∆4-isomer have antiproliferative effects 
on normal breast cells and increase apoptosis in both normal and malignant breast epithelium, presumably 
through decreased expression of the antiapoptotic proteins Bcl-2 and Bax (22). In addition, tibolone and its 3 β-
hydroxy metabolite and also the ∆4-isomer exert anti-invasive effects on breast cancer cell lines in vitro. 
Two recent smaller trials have suggested that tibolone may indeed be safe in women with a history of breast 
cancer: An observational study has recently found no increase in systemic recurrences or contralateral breast 
cancer in 156 breast cancer survivors who have received tibolone for 18 to 96 months when compared with 
placebo after completion of 5 years of tamoxifen (23). In addition, Kroiss et al. (24) have shown the efficacy of 
tibolone in the reduction of hot flushes in tamoxifen-treated breast cancer patients. Although only 70 patients 
were enrolled into the trial, none of the women in the tibolone arm experienced a recurrence during the 12 
months of treatment and no endometrial stimulation was observed in the tibolone/tamoxifen arm. 
The favorable therapeutic profile has led to the design of the "Livial Intervention following Breast Cancer; 
Efficacy, Recurrence, and Tolerability Endpoints" (LIBERATE) study, an international multicenter trial that has 
recruited >3,000 patients and that is expected to report a first analysis by end of 2007. The aim of the study is to 
show noninferiority of tibolone compared with placebo in respect to breast cancer recurrence and to show that 
tibolone is safe and effective in women with breast cancer and vasomotor symptoms. Recently, however, the use 
of tibolone has been associated with an increased relative risk for the development of breast cancer in a large 
cross-sectional cohort trial (25). Although it should be noted that in this study only 88 of the 7,140 women who 
developed breast cancer during the observational period had exclusively received tibolone as hormone treatment, 
this unexpected observation has prompted further investigation of an explanation for this finding. It can, at least 
partly, be explained by the widespread practice of "preferential prescribing": Women with a history of breast 
cancer or chronic breast disease and women from high breast cancer risk families are more likely to receive 
tibolone for alleviation of their climacteric symptoms than estrogen-progestin combinations because of the 
perceived "breast safety" of tibolone by many physicians (26, 27). 
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Table 3. Changes in intratumoral apoptosis index, and relative Bcl-2 and Bax gene expression in response to 14 
d of treatment (intent-to-treat group) 
 Baseline Surgery Change from baseline P* 
 Tibolone Placebo Tibolone Placebo Tibolone Placebo  
Apoptosis index (%)       0.031 
     n 41 40 44 48 39 39  
     Median 1.4 1.4 1.6 1.7 0 0.3  
     Mean (SE) 1.5 (0.12) 1.5 (0.11) 1.6 (0.12) 1.7 (0.10) 0 (0.08) 0.3 (0.08)  
Bcl-2 (%)       0.739 
     n 28 21 28 21 28 21  
     Median 0.8 0.9 1 1 0.1 0.1  
     Mean (SE) 0.8 (0.06) 0.9 (0.07) 1 (0.09) 1.1 (0.11) 0.2 (0.09) 0.3 (0.13)  
Bax (%)       0.642 
     n 28 21 28 21 28 21  
     Median 0.6 0.6 0.7 0.7 0.1 0  
     Mean (SE) 0.5 (0.04) 0.6 (0.04) 0.7 (0.08) 0.9 (0.15) 0.2 (0.08) 0.3 (0.15)  
NOTE: The relative Bcl-2 and Bax gene expression is depicted as the ratios of the specific transcript/28S transcript. *Wilcoxon test on 
treatment differences for change from baseline. 
We have studied the effects of tibolone on malignant breast tissue in an in vivo model that has been suggested to 
parallel long-term endocrine effects: Dowsett et al. (15) have recently shown that changes in intratumoral Ki67 
protein expression under neoadjuvant endocrine therapy can correspond to the disease-free survival in the large 
adjuvant ATAC Trial. Ki67 is therefore now increasingly used as an end point in neoadjuvant studies, and our 
observation of essentially unchanged Ki67 levels in biopsies from the placebo group that were taken 2 weeks 
apart underscore the appropriateness of this approach (28). Our results are also somewhat support observations 
by Valdivia et al. (29), who even showed that a 12-month treatment with tibolone leads to a reduction in Ki67 
expression and to a stimulation of apoptosis, albeit in normal breast tissue of postmenopausal women. Although, 
in contrast to their findings, we did not observe an increase in intratumoral apoptosis by tibolone, we did find a 
nominal but insignificant reduction in Ki67. The attenuated effect of tibolone that is seen in tumor tissue can at 
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least in part be explained by the fact that whereas in normal breast tissue the effect of tibolone is measured in 
more or less homogenous tissues, in malignant breast tumors the situation is considerably more complex: Core 
biopsies can contain considerably different fractions of tumor cells and tumor stroma, and the biological activity 
of tumor cells also varies from patient to patient, which could have somewhat weakened the effect of the 
compound. We have, however, no explanation for the fact that 14 days of placebo result in a significant increase 
of apoptosis. 
Table 4. Adverse events (all subjects treated group) 
 Tibolone (17 = 51) Placebo (17 = 51) 
Adverse events, total 17 (33%) 14 (28%) 
     Postprocedural pain 7 (14%) 4 (8%) 
     Asthenia 5 (10%) 5 (10%) 
     Pyrexia 4 (8%) 2 (4%) 
     Nausea 3 (6%) 1 (2%) 
     Dizziness 3 (6%) 0 (0%) 
     Headache 3 (6%) 0 (0%) 
Serious adverse events, total 1 (2%) 1 (2%) 
     Ischemic stroke 1 (2%) 0 (0%) 
     Postoperative wound infection 0 (0%) 1 (2%) 
Serious adverse event leading to discontinuation 1 (2%) 0 (0%) 
Death 0 (0%) 0 (0%) 
 
Taken together, the STEM trial has shown that tibolone, a commonly prescribed hormone replacement therapy, 
given for 14 days in postmenopausal women with ER+ breast cancer, has no adverse effect on the expression of 
the proliferation marker Ki-67 and on surrogate variables of apoptosis in malignant epithelium. To our 
knowledge, this is the first clinical trial that has investigated the proliferative and apoptotic effects of a hormone 
replacement therapy in breast cancer patients in the preoperative setting. If the still ongoing LIBERATE trial 
indeed shows that tibolone given for 5 years has no adverse effects on tumor recurrence, our results would 
complement previous findings by the IMPACT trial and thus provide further evidence for the usefulness of 
short-term neoadjuvant in vivo assays. Preoperative in vivo studies such as the one presented here might thus 
potentially allow us to predict the long-term outcomes of novel endocrine therapies in a small, safe, and short in 
vivo setting, and eventually help to avoid unnecessarily lengthy and considerably more expensive adjuvant trials 
in the future. 
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